首页> 美国卫生研究院文献>Oncology Letters >Gallic acid as a selective anticancer agent that induces apoptosis in SMMC-7721 human hepatocellular carcinoma cells
【2h】

Gallic acid as a selective anticancer agent that induces apoptosis in SMMC-7721 human hepatocellular carcinoma cells

机译:没食子酸作为选择性抗癌剂诱导SMMC-7721人肝癌细胞凋亡

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gallic acid (3,4,5-trihydroxybenzoic acid; GA) is a naturally occurring plant polyphenol, isolated from water caltrop, which has been reported to exert anticancer effects. The present study investigated the antiproliferative effects of GA on the HepG2 and SMMC-7721 human hepatocellular carcinoma (HCC) cell lines using MTT and colony formation assays. In particular, the underlying mechanism of GA-induced apoptosis in SMMC-7721 cells was studied in vitro by flow cytometry and western blotting. The results of the present study indicated that GA was capable of inhibiting the proliferation of HepG2 and SMMC-7721 cells in a time- and dose-dependent manner, as well as inducing the apoptosis of SMMC-7721 cells. GA induced caspase-3, caspase-9 and reactive oxygen species activity, elevated the expression of apoptosis regulator Bcl-2-like protein 4 and reduced the mitochondrial membrane potential in SMMC-7721 cells. When compared with HL-7702 normal human hepatocytes, GA demonstrated selective toxicity for HCC cells. In conclusion, GA is able to induce apoptosis in SMMC-7721 cells in vitro via mitochondrial-mediated pathways, and may possess the potential to be a novel therapeutic compound for use in the treatment of HCC.
机译:没食子酸(3,4,5-三羟基苯甲酸; GA)是一种天然存在的植物多酚,从水菱角中分离出来,据报道具有抗癌作用。本研究使用MTT和集落形成试验研究了GA对HepG2和SMMC-7721人肝细胞癌(HCC)细胞系的抗增殖作用。特别地,通过流式细胞术和蛋白质印迹体外研究了GA诱导的SMMC-7721细胞凋亡的潜在机制。本研究的结果表明,GA能够以时间和剂量依赖性方式抑制HepG2和SMMC-7721细胞的增殖,并诱导SMMC-7721细胞的凋亡。 GA诱导SMMC-7721细胞中的caspase-3,caspase-9和活性氧活性,提高凋亡调节因子Bcl-2-like蛋白4的表达并降低线粒体膜电位。与HL-7702正常人肝细胞相比,GA对HCC细胞具有选择性毒性。总之,GA能够通过线粒体介导的途径在体外诱导SMMC-7721细胞凋亡,并且可能具有成为治疗HCC的新型治疗化合物的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号